Medartis : Investor presentation at the Jefferies Global Healthcare conference

Building on our legacy −

growing beyond

Matthias Schupp, CEO

Jefferies Global Healthcare conference, 19 November 2025

Business highlights H1 2025

Organic revenue

growth

+15.3% CER

NeoOrtho

integration

On plan

KeriMedical

partnership

US entry

Guidance

FY 2025

14-16% CER

−	Total sales reached	−	NeoOrtho integration in	−	We secured the	−	Following satisfying trend in
	CHF 123.0 million,		Brazil on plan		remaining 53% stake in		H1, we raise our full-year

including three months of

sales from NeoOrtho in

Brazil from May onwards

− Core2 EBITDA margin sustained at 17.8% despite strong CHF and US tariffs

− Back-office consolidation and new production facility in Curitiba to be concluded early 2026

KeriMedical in July

− Market launch of the flagship product TOUCH in the USA

organic sales guidance to

14-16%

− Unchanged high-teens core EBITDA margin despite US tariffs headwind

1 Organic growth denotes the increase in sales at constant exchange rates (CER), excluding the impact of M&A (i.e. NeoOrtho).

2 Core figures exclude certain one-time, non-recurring and extraordinary items or items related to M&A 2

All segments with double-digit growth

15.8%

67%

18%

15%

16.8%

10.3%

17.8 16.0

16.0

Regional growth in %

(Organic core sales growth)

Sales breakdown by segment (inside) and H1 2025 organic growth in % (outside)

20.6

16.2

16.2

14.9 14.9

3.1

8.2 8.2

15.3 15.3

13.1

H1 2024

FY 2024

H1 2025

-9.5

EMEA US APAC LATAM Group

3

EBITDA | Core profitability increased thanks to balanced cost management

in % of net sales, rounded

21.4

-1.4

-3.6

16.4

-1.8

+1.4 PP

3.0 0.2

0.0

17.8

-0.8

17.0

− Core EBITDA margin increased +1.4 PP at CER

− 1.4 PP adverse FX impact

− Balanced OPEX management: Focus on growth investments while keeping overall cost discipline

− Accretive impact of NeoOrtho (only 2 months consolidated)

Reported EBITDA

margin H1 2024

FX Non-core items

Core EBITDA H1 2024

margin @CER

Gross profit effect

Improved OPEX ratio

Associate result (KeriMedical)

NeoOrtho Core EBITDA H1 2025

margin

Non-core items

Reported EBITDA H1 2025

margin 4

ONE TEAM

Executive Management Board

KeriMedical Advisory Board

DOUGAL BENDJABALLAH & BERNARD PRANDI

Cold Fusion Brazil Lead

FREDERICO RINKE

COO

MARIO DELLA CASA

CFO

DIRK KIRSTEN

President US

DAVID THONI

President EMEA

MAREIKE LOCH

CHRO

CAROLINE KNOERI

EVP R&D

MARC AMMANN

5